Dogwood Therapeutics
DWTX
10 hedge funds and large institutions have $76.5K invested in Dogwood Therapeutics in 2024 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 14 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
1.52% less ownership
Funds ownership: 3.83% → 2.31% (-1.5%)
58% less capital invested
Capital invested by funds: $180K → $76.5K (-$104K)
58% less funds holding
Funds holding: 24 → 10 (-14)
93% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$33.9K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$5.64K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.31K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$7 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$35.5K |
| 2 |
HF
HRT Financial
New York
|
-$13K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$9.08K |
| 4 |
State Street
Boston,
Massachusetts
|
-$8.98K |
| 5 |
MCG
McCollum Christoferson Group
Amherst,
New York
|
-$5.7K |
DWTX Hedge Fund Activity: Q4 2024 in Review
10 of the 7,608 institutional investors tracked by Wall St. Rank reported a position in Dogwood Therapeutics (DWTX) for Q4 2024, worth a combined $76.5K — down 58% from $180K a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of DWTX and 1 opened new positions — a net loss of 13 holders — while 3 trimmed existing stakes and 4 added.
The largest buyer was UBS Group, adding an estimated $33.9K. The largest seller was Vanguard Group, exiting entirely with an estimated $35.5K sold.
- 10 institutional investors held Dogwood Therapeutics (DWTX) as of Q4 2024, down from 24 in Q3 2024.
- Funds reported $76.5K of Dogwood Therapeutics stock for Q4 2024, down 58% quarter-over-quarter.
- 1 fund opened new Dogwood Therapeutics positions in Q4 2024 and 14 closed out, a net change of -13 holders.
- The largest Dogwood Therapeutics buyer in Q4 2024 was UBS Group, an estimated $33.9K added.
- The largest Dogwood Therapeutics seller in Q4 2024 was Vanguard Group, an estimated $35.5K sold.
Based on aggregated 13F filings for Q4 2024.